Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis

NCT00037687 is registered in ClinicalTrials.gov with ICOS Corporation as lead sponsor.

NCT NCT00037687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00037687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Demonstrate the Safety and Efficacy of Recombinant Platelet-Activating Factor Acetylhydrolase (rPAF-AH, Pafase®) for Reducing 28 Day All Cause Mortality in Patients With Severe Sepsis
Lead sponsor
ICOS Corporation
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2001
Completion date
December 31, 2004
Enrollment
2,500
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis